Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease

Identifieur interne : 006362 ( Main/Merge ); précédent : 006361; suivant : 006363

Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease

Auteurs : François Tison [France] ; Farid Yekhlef [France] ; Virginie Chrysostome [France] ; Eric Balestre [France] ; Niall P. Quinn [Royaume-Uni] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]

Source :

RBID : ISTEX:1229E5C7D229E3791022ECCCACCBC9E6DC87648F

English descriptors

Abstract

We analyzed parkinsonian features in multiple system atrophy (MSA) compared with age‐ and disease duration‐matched Parkinson's disease (PD) patients, and assessed the applicability of the Unified Parkinson's Disease Rating Scale (UPDRS) ‐III motor scale as a means of rating their severity. Cross‐sectional analysis of parkinsonism was done using UPDRS‐III, International Cerebellar Atatia Rating Scale, and disability scales (Hoehn and Yahr [H&A], Schwab and England, Katz and Lawton) in 50 unselected MSA patients and in 50 matched PD patients. At symptom onset, falls occurred 10 times more frequently in MSA, whereas limb tremor was 10 times more common in PD. At first visit (10.2 months), hemiparkinsonism and pill‐rolling rest tremor were less common in MSA. Hypomimia, atypical rest, postural or action tremor, as well as postural instability were more frequent in MSA. At study examination (62.4 months), parkinsonian signs in MSA patients were more frequently symmetrical and associated with axial rigidity, antecollis and postural instability. A levodopa response of >50% was seen in <10% of MSA patients. Modified H&Y stages (3.2 ± 1.3 vs. 2.2 ± 0.78) and UPDRS‐III scores (48.14 ± 19.5 vs. 31.74 ± 12.9) were significantly (P = 0.0001) higher in MSA. The internal consistency of the UPDRS‐III was fair in MSA patients (Cronbach's α >0.90), and correlated well with marked dependency on the Schwab and England and Katz and Lawton scales. Factor structure analysis of UPDRS‐III in MSA showed five clinically distinct subscores accounting for 74% of the variance, differing from PD by the dependency of the face–speech and limb bradykinesia items and independence of the postural–action tremor from the rest tremor items. There was a significant correlation (R2 = 0.70, P = 0.001) between ICARS ataxia and UPDRS‐III scores in MSA patients. Results confirm a distinct profile of parkinsonism in MSA and greater severity and disability compared with PD. It also indicates that the UPDRS‐III provides a useful severity measure of parkinsonism in MSA, albeit contaminated by additional cerebellar dysfunction. © 2002 Movement Disorder Society

Url:
DOI: 10.1002/mds.10171

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:1229E5C7D229E3791022ECCCACCBC9E6DC87648F

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease</title>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
</author>
<author>
<name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name>
</author>
<author>
<name sortKey="Chrysostome, Virginie" sort="Chrysostome, Virginie" uniqKey="Chrysostome V" first="Virginie" last="Chrysostome">Virginie Chrysostome</name>
</author>
<author>
<name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name>
</author>
<author>
<name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<country>Autriche</country>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1229E5C7D229E3791022ECCCACCBC9E6DC87648F</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10171</idno>
<idno type="url">https://api.istex.fr/document/1229E5C7D229E3791022ECCCACCBC9E6DC87648F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000007</idno>
<idno type="wicri:Area/Istex/Curation">000007</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C48</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Tison F:parkinsonism:in:multiple</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12210859</idno>
<idno type="wicri:Area/PubMed/Corpus">003A22</idno>
<idno type="wicri:Area/PubMed/Curation">003A22</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003993</idno>
<idno type="wicri:Area/Ncbi/Merge">000829</idno>
<idno type="wicri:Area/Ncbi/Curation">000829</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000829</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Tison F:parkinsonism:in:multiple</idno>
<idno type="wicri:Area/Main/Merge">006362</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease</title>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Chrysostome, Virginie" sort="Chrysostome, Virginie" uniqKey="Chrysostome V" first="Virginie" last="Chrysostome">Virginie Chrysostome</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut National de la Santé et de la Recherche Médicale U‐330, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Klinik für Neurologie, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Klinik für Neurologie, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-07">2002-07</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="701">701</biblScope>
<biblScope unit="page" to="709">709</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1229E5C7D229E3791022ECCCACCBC9E6DC87648F</idno>
<idno type="DOI">10.1002/mds.10171</idno>
<idno type="ArticleID">MDS10171</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Activities of Daily Living (classification)</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Disability Evaluation</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Multiple System Atrophy (classification)</term>
<term>Multiple System Atrophy (diagnosis)</term>
<term>Multiple System Atrophy (drug therapy)</term>
<term>Neurologic Examination (drug effects)</term>
<term>Neurologic Examination (statistics & numerical data)</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (classification)</term>
<term>Parkinsonian Disorders (diagnosis)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Reproducibility of Results</term>
<term>UPDRS‐III</term>
<term>dependency</term>
<term>factor analysis</term>
<term>internal consistency</term>
<term>multiple system atrophy</term>
<term>parkinsonism</term>
<term>severity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en">
<term>Activities of Daily Living</term>
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Disability Evaluation</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Reproducibility of Results</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We analyzed parkinsonian features in multiple system atrophy (MSA) compared with age‐ and disease duration‐matched Parkinson's disease (PD) patients, and assessed the applicability of the Unified Parkinson's Disease Rating Scale (UPDRS) ‐III motor scale as a means of rating their severity. Cross‐sectional analysis of parkinsonism was done using UPDRS‐III, International Cerebellar Atatia Rating Scale, and disability scales (Hoehn and Yahr [H&A], Schwab and England, Katz and Lawton) in 50 unselected MSA patients and in 50 matched PD patients. At symptom onset, falls occurred 10 times more frequently in MSA, whereas limb tremor was 10 times more common in PD. At first visit (10.2 months), hemiparkinsonism and pill‐rolling rest tremor were less common in MSA. Hypomimia, atypical rest, postural or action tremor, as well as postural instability were more frequent in MSA. At study examination (62.4 months), parkinsonian signs in MSA patients were more frequently symmetrical and associated with axial rigidity, antecollis and postural instability. A levodopa response of >50% was seen in <10% of MSA patients. Modified H&Y stages (3.2 ± 1.3 vs. 2.2 ± 0.78) and UPDRS‐III scores (48.14 ± 19.5 vs. 31.74 ± 12.9) were significantly (P = 0.0001) higher in MSA. The internal consistency of the UPDRS‐III was fair in MSA patients (Cronbach's α >0.90), and correlated well with marked dependency on the Schwab and England and Katz and Lawton scales. Factor structure analysis of UPDRS‐III in MSA showed five clinically distinct subscores accounting for 74% of the variance, differing from PD by the dependency of the face–speech and limb bradykinesia items and independence of the postural–action tremor from the rest tremor items. There was a significant correlation (R2 = 0.70, P = 0.001) between ICARS ataxia and UPDRS‐III scores in MSA patients. Results confirm a distinct profile of parkinsonism in MSA and greater severity and disability compared with PD. It also indicates that the UPDRS‐III provides a useful severity measure of parkinsonism in MSA, albeit contaminated by additional cerebellar dysfunction. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.10171">
<ISTEX>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease</title>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
</author>
<author>
<name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name>
</author>
<author>
<name sortKey="Chrysostome, Virginie" sort="Chrysostome, Virginie" uniqKey="Chrysostome V" first="Virginie" last="Chrysostome">Virginie Chrysostome</name>
</author>
<author>
<name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name>
</author>
<author>
<name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<country>Autriche</country>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1229E5C7D229E3791022ECCCACCBC9E6DC87648F</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10171</idno>
<idno type="url">https://api.istex.fr/document/1229E5C7D229E3791022ECCCACCBC9E6DC87648F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000007</idno>
<idno type="wicri:Area/Istex/Curation">000007</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C48</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Tison F:parkinsonism:in:multiple</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease</title>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Chrysostome, Virginie" sort="Chrysostome, Virginie" uniqKey="Chrysostome V" first="Virginie" last="Chrysostome">Virginie Chrysostome</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut National de la Santé et de la Recherche Médicale U‐330, Epidémiologie et Biostatistiques Centre Hospitalo‐Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Klinik für Neurologie, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Klinik für Neurologie, University Hospital, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-07">2002-07</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="701">701</biblScope>
<biblScope unit="page" to="709">709</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1229E5C7D229E3791022ECCCACCBC9E6DC87648F</idno>
<idno type="DOI">10.1002/mds.10171</idno>
<idno type="ArticleID">MDS10171</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Parkinson's disease</term>
<term>UPDRS‐III</term>
<term>dependency</term>
<term>factor analysis</term>
<term>internal consistency</term>
<term>multiple system atrophy</term>
<term>parkinsonism</term>
<term>severity</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We analyzed parkinsonian features in multiple system atrophy (MSA) compared with age‐ and disease duration‐matched Parkinson's disease (PD) patients, and assessed the applicability of the Unified Parkinson's Disease Rating Scale (UPDRS) ‐III motor scale as a means of rating their severity. Cross‐sectional analysis of parkinsonism was done using UPDRS‐III, International Cerebellar Atatia Rating Scale, and disability scales (Hoehn and Yahr [H&A], Schwab and England, Katz and Lawton) in 50 unselected MSA patients and in 50 matched PD patients. At symptom onset, falls occurred 10 times more frequently in MSA, whereas limb tremor was 10 times more common in PD. At first visit (10.2 months), hemiparkinsonism and pill‐rolling rest tremor were less common in MSA. Hypomimia, atypical rest, postural or action tremor, as well as postural instability were more frequent in MSA. At study examination (62.4 months), parkinsonian signs in MSA patients were more frequently symmetrical and associated with axial rigidity, antecollis and postural instability. A levodopa response of >50% was seen in <10% of MSA patients. Modified H&Y stages (3.2 ± 1.3 vs. 2.2 ± 0.78) and UPDRS‐III scores (48.14 ± 19.5 vs. 31.74 ± 12.9) were significantly (P = 0.0001) higher in MSA. The internal consistency of the UPDRS‐III was fair in MSA patients (Cronbach's α >0.90), and correlated well with marked dependency on the Schwab and England and Katz and Lawton scales. Factor structure analysis of UPDRS‐III in MSA showed five clinically distinct subscores accounting for 74% of the variance, differing from PD by the dependency of the face–speech and limb bradykinesia items and independence of the postural–action tremor from the rest tremor items. There was a significant correlation (R2 = 0.70, P = 0.001) between ICARS ataxia and UPDRS‐III scores in MSA patients. Results confirm a distinct profile of parkinsonism in MSA and greater severity and disability compared with PD. It also indicates that the UPDRS‐III provides a useful severity measure of parkinsonism in MSA, albeit contaminated by additional cerebellar dysfunction. © 2002 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.</title>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
<affiliation wicri:level="1">
<nlm:affiliation>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France. francois.tison@chu-bordeaux.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo-Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name>
</author>
<author>
<name sortKey="Chrysostome, Virginie" sort="Chrysostome, Virginie" uniqKey="Chrysostome V" first="Virginie" last="Chrysostome">Virginie Chrysostome</name>
</author>
<author>
<name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name>
</author>
<author>
<name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P" last="Quinn">Niall P. Quinn</name>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<country>Autriche</country>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K" last="Wenning">Gregor K. Wenning</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12210859</idno>
<idno type="pmid">12210859</idno>
<idno type="doi">10.1002/mds.10171</idno>
<idno type="wicri:Area/PubMed/Corpus">003A22</idno>
<idno type="wicri:Area/PubMed/Curation">003A22</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003993</idno>
<idno type="wicri:Area/Ncbi/Merge">000829</idno>
<idno type="wicri:Area/Ncbi/Curation">000829</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000829</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Tison F:parkinsonism:in:multiple</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.</title>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
<affiliation wicri:level="1">
<nlm:affiliation>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France. francois.tison@chu-bordeaux.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie, Epidémiologie et Biostatistiques Centre Hospitalo-Universitaire de Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name>
</author>
<author>
<name sortKey="Chrysostome, Virginie" sort="Chrysostome, Virginie" uniqKey="Chrysostome V" first="Virginie" last="Chrysostome">Virginie Chrysostome</name>
</author>
<author>
<name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name>
</author>
<author>
<name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P" last="Quinn">Niall P. Quinn</name>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<country>Autriche</country>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K" last="Wenning">Gregor K. Wenning</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Activities of Daily Living (classification)</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Disability Evaluation</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Multiple System Atrophy (classification)</term>
<term>Multiple System Atrophy (diagnosis)</term>
<term>Multiple System Atrophy (drug therapy)</term>
<term>Neurologic Examination (drug effects)</term>
<term>Neurologic Examination (statistics & numerical data)</term>
<term>Parkinsonian Disorders (classification)</term>
<term>Parkinsonian Disorders (diagnosis)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Reproducibility of Results</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en">
<term>Activities of Daily Living</term>
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Disability Evaluation</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Reproducibility of Results</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We analyzed parkinsonian features in multiple system atrophy (MSA) compared with age- and disease duration-matched Parkinson's disease (PD) patients, and assessed the applicability of the Unified Parkinson's Disease Rating Scale (UPDRS) -III motor scale as a means of rating their severity. Cross-sectional analysis of parkinsonism was done using UPDRS-III, International Cerebellar Atatia Rating Scale, and disability scales (Hoehn and Yahr [H&A], Schwab and England, Katz and Lawton) in 50 unselected MSA patients and in 50 matched PD patients. At symptom onset, falls occurred 10 times more frequently in MSA, whereas limb tremor was 10 times more common in PD. At first visit (10.2 months), hemiparkinsonism and pill-rolling rest tremor were less common in MSA. Hypomimia, atypical rest, postural or action tremor, as well as postural instability were more frequent in MSA. At study examination (62.4 months), parkinsonian signs in MSA patients were more frequently symmetrical and associated with axial rigidity, antecollis and postural instability. A levodopa response of >50% was seen in <10% of MSA patients. Modified H&Y stages (3.2 +/- 1.3 vs. 2.2 +/- 0.78) and UPDRS-III scores (48.14 +/- 19.5 vs. 31.74 +/- 12.9) were significantly (P = 0.0001) higher in MSA. The internal consistency of the UPDRS-III was fair in MSA patients (Cronbach's alpha >0.90), and correlated well with marked dependency on the Schwab and England and Katz and Lawton scales. Factor structure analysis of UPDRS-III in MSA showed five clinically distinct subscores accounting for 74% of the variance, differing from PD by the dependency of the face-speech and limb bradykinesia items and independence of the postural-action tremor from the rest tremor items. There was a significant correlation (R(2) = 0.70, P = 0.001) between ICARS ataxia and UPDRS-III scores in MSA patients. Results confirm a distinct profile of parkinsonism in MSA and greater severity and disability compared with PD. It also indicates that the UPDRS-III provides a useful severity measure of parkinsonism in MSA, albeit contaminated by additional cerebellar dysfunction.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006362 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006362 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     ISTEX:1229E5C7D229E3791022ECCCACCBC9E6DC87648F
   |texte=   Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024